Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry - PubMed (original) (raw)
Comparative Study
Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry
Stephen Waldek et al. Genet Med. 2009 Nov.
Free article
Abstract
Purpose: To evaluate life expectancy and cause of death among patients with Fabry disease, an X-linked lysosomal storage disorder.
Methods: Data from 2848 patients in the Fabry Registry were summarized using descriptive statistics. Life expectancy at birth was compared with that of the United States general population.
Results: As of August 2008, 75 of 1422 males and 12 of 1426 females in the Fabry Registry were reported to have died. The 87 deceased patients were diagnosed at a much older age than other patients in the Fabry Registry: median age at diagnosis was 40 vs. 24 years in males and 55 vs. 33 years in females. The life expectancy of males with Fabry disease was 58.2 years, compared with 74.7 years in the general population of the United States. The life expectancy of females with Fabry disease was 75.4 years, compared with 80.0 years in the United States general population. The most common cause of death among both genders was cardiovascular disease. Most (57%) patients who died of cardiovascular disease had previously received renal replacement therapy.
Conclusions: Most deceased Fabry Registry patients exhibited serious cardiac and renal dysfunction. Late diagnosis may have contributed to the early deaths of these patients.
Similar articles
- End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG. Ortiz A, et al. Nephrol Dial Transplant. 2010 Mar;25(3):769-75. doi: 10.1093/ndt/gfp554. Epub 2009 Oct 21. Nephrol Dial Transplant. 2010. PMID: 19846394 - Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, Ortiz A, Patel MR, Sims K, Waldek S, Warnock DG, Wilcox WR. Hopkin RJ, et al. Mol Genet Metab. 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13. Mol Genet Metab. 2016. PMID: 27510433 Clinical Trial. - Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
Sims K, Politei J, Banikazemi M, Lee P. Sims K, et al. Stroke. 2009 Mar;40(3):788-94. doi: 10.1161/STROKEAHA.108.526293. Epub 2009 Jan 15. Stroke. 2009. PMID: 19150871 - Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G. Tuttolomondo A, et al. Curr Pharm Des. 2013;19(33):5974-96. doi: 10.2174/13816128113199990352. Curr Pharm Des. 2013. PMID: 23448451 Review. - Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM, Tylki-Szymańska A, Hilz MJ. Schaefer RM, et al. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Drugs. 2009. PMID: 19852524 Review.
Cited by
- FabryScan: a screening tool for early detection of Fabry disease.
Arning K, Naleschinski D, Maag R, Biegstraaten M, Kropp P, Lorenzen J, Hollak CE, van Schaik IN, Harten P, Zeuner RA, Binder A, Baron R. Arning K, et al. J Neurol. 2012 Nov;259(11):2393-400. doi: 10.1007/s00415-012-6619-y. Epub 2012 Aug 10. J Neurol. 2012. PMID: 22878429 - Innate and Adaptive Immune Response in Fabry Disease.
Mauhin W, Lidove O, Masat E, Mingozzi F, Mariampillai K, Ziza JM, Benveniste O. Mauhin W, et al. JIMD Rep. 2015;22:1-10. doi: 10.1007/8904_2014_371. Epub 2015 Feb 18. JIMD Rep. 2015. PMID: 25690728 Free PMC article. - Prevalence of Raynaud phenomenon and nailfold capillaroscopic abnormalities in Fabry disease: a cross-sectional study.
Deshayes S, Auboire L, Jaussaud R, Lidove O, Parienti JJ, Triclin N, Imbert B, Bienvenu B, Aouba A. Deshayes S, et al. Medicine (Baltimore). 2015 May;94(20):e780. doi: 10.1097/MD.0000000000000780. Medicine (Baltimore). 2015. PMID: 25997047 Free PMC article. - Diagnosis and Screening of Patients with Fabry Disease.
Vardarli I, Rischpler C, Herrmann K, Weidemann F. Vardarli I, et al. Ther Clin Risk Manag. 2020 Jun 22;16:551-558. doi: 10.2147/TCRM.S247814. eCollection 2020. Ther Clin Risk Manag. 2020. PMID: 32606714 Free PMC article. Review. - Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation.
Pietilä-Effati P, Söderström J, Saarinen JT, Löyttyniemi E, Kantola I. Pietilä-Effati P, et al. Mol Genet Genomic Med. 2022 May;10(5):e1915. doi: 10.1002/mgg3.1915. Epub 2022 Mar 4. Mol Genet Genomic Med. 2022. PMID: 35246967 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials